Eli Lilly and Novo Nordisk May Soon Sell Weight Loss Drugs on the Planned TrumpRx. Could This Further Boost the Healthcare ...

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. Eli Lilly has advanced in the triple-digits ...

Eli Lilly stock has regained all-time highs, outpacing rivals in the obesity drug market. Click here to read my latest ...

Novo Nordisk cuts obesity drug prices to compete with Eli Lilly, offering new patient deals and nationwide access.

Eli Lilly and Company (NYSE: LLY) is one of the 15 Best Aggressive Growth Stocks to Buy Right Now. On November 7, TD Cowen ...

Let’s delve into the details of each of the evaluated factors, but first, for a quick background: With a $917 Bil market cap, ...

These branded GLP-1 medications will be made available to both MangoRx and PeachesRx customers via Eli Lilly’s LillyDirect® Self Pay Pharmacy Solutions and Novo Nordisk’s NovoCare Pharmacy. Through ...

The two drugmakers swiftly denied any affiliation with Mangoceuticals, who claimed it had partnered with them.

Eli Lilly’s Zepbound push is getting a “Queer Eye” makeover with the help of fashion expert Tan France, who is joining the ...

Novo Nordisk and Eli Lilly denied weight-loss drug partnership with Mangoceuticals on Thursday, hours after the telehealth ...

Eli Lilly is dropping CVS Health's drug benefit plan for its employees after the healthcare conglomerate stopped covering the company's weight-loss drug in favor of Novo Nordisk's rival medication, ...

Eli Lilly and Company LLY reported third-quarter 2025 adjusted earnings per share (“EPS”) of $7.02, which beat the Zacks Consensus Estimate of $6.02 per share. In the year-ago quarter, Lilly recorded ...